New drug duo targets tough liver cancer mutation
NCT ID NCT06811116
Summary
This study is testing whether adding a new drug called sapanisertib to an existing drug, cabozantinib, works better than cabozantinib alone for people with advanced liver cancer that has a specific genetic change (β-catenin mutation). The first part of the trial will find the safest dose of the combination, and the second part will compare how long patients' cancer is controlled with the two-drug combo versus the single drug. The goal is to see if blocking more cancer growth pathways can help control this hard-to-treat cancer for longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oregon Health and Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITINGIrvine, California, 92612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.